Bicara Therapeutics Inc. ...

15.65
0.14 (0.90%)
At close: Apr 24, 2025, 3:59 PM
15.63
-0.16%
After-hours: Apr 24, 2025, 04:05 PM EDT
0.90%
Bid 13.7
Market Cap 853.56M
Revenue (ttm) n/a
Net Income (ttm) -68M
EPS (ttm) -4.05
PE Ratio (ttm) -3.87
Forward PE -4.93
Analyst Buy
Ask 17.73
Volume 258,804
Avg. Volume (20D) 539,322.2
Open 15.49
Previous Close 15.51
Day's Range 15.14 - 15.78
52-Week Range 8.91 - 28.09
Beta -1.41

About BCAX

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 55
Stock Exchange NASDAQ
Ticker Symbol BCAX
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for BCAX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 110.80% from the latest price.

Stock Forecasts
4 months ago
+7.98%
Bicara Therapeutics shares are trading higher afte... Unlock content with Pro Subscription